Potential target antigens for immunotherapy identified by serological expression cloning (SEREX)

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Cancer immunotherapy requires identifying antigens recognized by immune effector cells.
• Serological Analysis of Recombinant Tumor cDNA Expression Libraries (SEREX) is a method for discovering tumor antigens based on patient immune responses.

Purpose of the Study:

• To detail the evaluation process for newly identified tumor antigens.
• To present the identification and characterization of a novel breast cancer antigen, NY-BR-1.

Main Methods:

• Utilized SEREX to screen autologous breast cancer cDNA expression libraries.
• Applied a multi-step algorithm including expression analysis, serological testing, epitope identification, and T-cell assays for antigen validation.

Main Results:

• Successfully identified a novel breast cancer differentiation antigen, named NY-BR-1.
• Demonstrated the tumor-associated expression and immunogenicity of NY-BR-1.

Conclusions:

• NY-BR-1 is a promising target antigen for active immunotherapy against breast cancer.
• The comprehensive evaluation strategy ensures the potential of identified antigens as vaccine targets.